Pivotal is a software company that provides digital transformation technology and services. Pivotal’s cloud native platform drives software innovation for many of the world’s most admired brands. The Company combines the Silicon Valley state of mind, modern approach, and infrastructure with organizations’ core expertise and values. Pivotal enables the leading companies in the world to innovate by employing an approach focused on building software.
Type
Public
HQ
San Francisco, US
Founded
2012
Size (employees)
2,129 (est)
Website
pivotal.io
Pivotal was founded in 2012 and is headquartered in San Francisco, US
Report incorrect company information

Key People/Management at Pivotal

Paul Maritz

Paul Maritz

Chairman of the Board
Rob Mee

Rob Mee

CEO
Bill Cook

Bill Cook

President
Scott Yara

Scott Yara

Senior Vice President, Products
Andy Cohen

Andy Cohen

General Counsel
Cynthia Gaylor

Cynthia Gaylor

CFO
Show more

Pivotal Office Locations

Pivotal has offices in San Francisco, Singapore, London, Cambridge and in 10 other locations
San Francisco, US (HQ)
875 Howard St
Arlington, US
2221 S Clark St
Boulder, US
200 1701 Pearl St
Cambridge, US
145 Broadway
Chicago, US
1214 222 W Merchandise Mart Plaza
Denver, US
1644 Platte St
Show all (15)
Report incorrect company information

Pivotal Financials and Metrics

Pivotal Financials

Pivotal's revenue was reported to be $509.44 m in FY, 2018 which is a 22.4% increase from the previous period.
USD

Revenue (FY, 2018)

509.4 m

Revenue growth (FY, 2017 - FY, 2018), %

22.4%

Gross profit (FY, 2018)

281 m

Gross profit margin (FY, 2018), %

55.2%

Net income (FY, 2018)

(163.5 m)

EBIT (FY, 2018)

(168.3 m)

Cash (2-Feb-2018)

73 m
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

280.9 m416.3 m509.4 m

Revenue growth, %

48%22%

Cost of goods sold

187.3 m234.3 m228.4 m

Gross profit

93.5 m181.9 m281 m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

88.2 m105.2 m110.1 m121.2 m126 m13 m

Cost of goods sold

57.3 m55.9 m60.3 m59 m56.3 m55.5 m

Gross profit

30.8 m49.3 m49.9 m62.2 m69.7 m(42.5 m)

Gross profit Margin, %

35%47%45%51%55%(328%)
USDFY, 2017FY, 2018

Cash

133.9 m73 m

Accounts Receivable

145.4 m210.7 m

Current Assets

328.7 m366.7 m

PP&E

29 m32 m
USDFY, 2016FY, 2017FY, 2018

Net Income

(282.7 m)(232.9 m)(163.5 m)

Depreciation and Amortization

32.8 m24.6 m22.2 m

Accounts Payable

(300 k)(6 m)12.6 m

Cash From Operating Activities

29.2 m(166.4 m)(116.5 m)
USDY, 2018

Revenue/Employee

268 k

Financial Leverage

1.6 x
Show all financial metrics

Pivotal Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018

Paying Business Customers

75 180 275 319

ISVs Integrated

75

Patents (US)

118

Patents (foreign)

22
Show all operating metrics

Pivotal Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Neo Innovation, Inc. February 28, 2016
Slice of Lime January 12, 2016
CloudCredo December 21, 2015
Xtreme Labs Inc October 02, 2013
Cubox
New Context (Singapore)
Proof Innovation Labs

Pivotal Revenue Breakdown

Embed Graph

Pivotal revenue breakdown by business segment: 66.2% from Services and 33.8% from Subscription

Report incorrect company information

Pivotal Online and Social Media Presence

Embed Graph
Report incorrect company information

Pivotal News and Updates

Mezzion Pharma and NHLBI-Funded Pediatric Heart Network Complete Enrollment in a Pivotal Phase 3 Clinical Trial of Udenafil in Adolescents with Fontan Surgical Palliation - an Orphan Drug Indication

SEOUL, South Korea and BETHESDA, Md., June 22, 2018 /PRNewswire/ -- Mezzion Pharma and the National Heart, Lung, and Blood Institute (NHLBI) today announced that it has completed enrollment of their FUEL trial, a pivotal Phase 3 efficacy and safety trial of udenafil for the treatment of...

Impel NeuroPharma Announces FDA Clearance of IND for Pivotal Phase 3 Study of INP104 for Acute Treatment of Migraine

SEATTLE, June 22, 2018 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that...

Impel NeuroPharma Announces FDA Clearance of IND for Pivotal Phase 3 Study of INP104 for Acute Treatment of Migraine

SEATTLE, June 22, 2018 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that...

Impel NeuroPharma Announces FDA Clearance of IND for Pivotal Phase 3 Study of INP104 for Acute Treatment of Migraine

SEATTLE, June 22, 2018 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that...

Maxor Appoints New CFO at Pivotal Point in the Company's Transformation

AMARILLO, Texas, June 19, 2018 /PRNewswire/ -- Maxor National Pharmacy Services, LLC (Maxor) today announced the appointment of David G. Wheeler, CPA as Chief Financial Officer.  Wheeler brings decades of executive leadership experience to Maxor, including more than fifteen years of experi...
Show more
Report incorrect company information